Navigantis recently announced the first successful neurovascular clinical cases performed with its Vasco interventional robotic platform.
The Miami-based company designed its Vasco platform for patients with neurovascular disorders, including acute ischemic stroke. It conducted first-in-human cases in 2022. In those cases, the platform’s previous generation successfully performed robotic embolization of liver tumors.
Navigantis said its neurovascular interventional robotic clinical trial includes patients undergoing diagnostic cerebral angiogram, brain tumor embolization and mechanical thrombectomy for ischemic stroke. Dong Joon Kim of the Severance Hospital in Seoul, South Korea, leads the study.
“These first successful robotic cases are a major stepping stone towards treating more complex neurovascular diseases,” said Kim.
Navigantis says it aims to empower physicians to deliver “uncompromised neurovascular care.” The company wants to create “the new frontier in surgical robotics.” Mor Dayan, CEO of Navigantis, said the first clinical cases mark an important milestone for the company.
“The Vasco robotic platform has the potential to redefine how we approach the most complex and time-sensitive neurovascular procedures, ultimately improving both patient outcomes and procedural efficiencies,” Dayan said. “This is one of the first steps towards enabling robotic telesurgery for stroke patients, which could dramatically reduce response times and enhance access to timely critical care.”
